Syndax Pharmaceuticals - SNDX Earnings per share for the last twelve months

The implementation of AI screening accelerates molecule discovery, but slow testing cycles constrain growth, as confirmed by the rolling per-share profit indicator on the GURU.Markets portal, where the value -2.38 corresponds to the current metric. The transition to the commercialization of leukemia therapies creates a stable cash flow, while the breakthrough menin inhibitors in the Syndax Pharmaceuticals (SNDX) pipeline fully leverage the company's scientific and medical potential.
Metric breakdowns and analytics for Syndax Pharmaceuticals (SNDX)

The integration of green chemistry principles and sustainable packaging into the drug development processes of Syndax Pharmaceuticals (SNDX) directly impacts operating expenses, shaping the business's bottom-line profitability. The current value of -2.38 reflects the rolling total annual income divided by the number of shares, allowing for a real-time assessment of capitalization efficiency and the fundamental value of an investor's stake through the 12-month net income per share.